Dermapharm Holding SE buy Ruckelsbuckel
Start price
02.08.22
/
40%
€55.50
Target price
02.08.23
€101.00
Performance (%)
-0.36%
End price
09.08.22
€55.30
Summary
This prediction ended on 09.08.22 with a price of €55.30. During the runtime of the prediction for Dermapharm Holding SE the price only changed by -0.36%. Ruckelsbuckel has 40% into this predictionDermapharm Holding is a Munich-based pharmaceutical company that develops innovative drug formulations and medical devices. It is listed on the Frankfurt Stock Exchange and has a strong presence in Germany and Europe. The company's product portfolio includes preparations for both prescription and over-the-counter drugs, as well as medical devices used in dermatology and urology. Dermapharm Holding differentiates itself from competitors by focusing on niche markets and developing new products in-house through its research and development activities.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Dermapharm Holding SE | -4.970% | -4.970% | -30.537% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% |
According to Ruckelsbuckel what are the pros and cons of Dermapharm Holding SE for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Undervalued
positive Cash Flow expected
Good rating
High Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Very capable Management
Very good company culture
Innovative
Some uniques
Growths faster than the competition
Stable Large shareholder and/or long term investor
Top 10 in its market
Very Future proof/growth oriented business model
Differentiated customer and product portfolio
Cons
Low dividend yield expected
High risks in the balance sheet
Little known brand
Sustainability is little important
High risks for its business
Significant cyclical dependencies
Comments by Ruckelsbuckel for this prediction
In the thread Dermapharm Holding SE diskutieren
Buy mit Kursziel 101,0